The present invention relates to a melt composite comprising one or more curcuminoids and a carrier selected from rice bran extract, mannitol, maltodextrin and mixtures thereof. The invention also provides a process for preparation of the melt composite, wherein the mixture of curcuminoids, rice bran extract, mannitol, maltodextrin and mixture thereof may be subjected to controlled conditions of heating and granulation. The melt composite may also be optionally comprised of one more excipient suitable for use for human consumption. Curcuminoid composites can be formulated in suitable solid, liquid or semisolid compositions. Curcuminoid composites and the compositions thereof, exhibit rapid dissolution and enhanced bioavailability.

Rhinoceros horn analogues and methods of synthesis thereof. Compounds with medicinal effects can be incorporated into the analogues. Genetic fingerprints can also be incorporated into the analogues. The analogues can be formulated into compositions.

An object of the present invention is to provide a pharmaceutical composition having abuse deterrent properties and thereby prevent the abuse of a pharmacologically active component by an abuser (abuse through snorting, abuse through injection, or abuse through snorting or injection of a temporarily extracted drug). The present invention provides a pharmaceutical composition having abuse deterrent properties that possesses both a physical barrier and a chemical barrier to being abused by an abuser, a method for producing the same and a method for using the same.

The present invention relates to use of a composition in the manufacture of a health care product or medicament for preventing and treating leucopenia induced by radiotherapy or chemotherapy. The composition is made from raw materials comprising 5 to 200 parts by weight of Ganoderma, 5 to 150 parts by weight of Radix Panacis Quinquefolii or Radix Et Rhizoma Ginseng, 1 to 90 parts by weight of fermented Cordyceps sinensis powder and/or 1 to 120 parts by weight of Cordyceps, or is a composition consisting of water and/or alcohol extracts of the above raw materials as active components.

The present invention relates to storage stable nanoparticulate compositions of piperazine compounds. The pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer are also described.

A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

The present invention relates to a novel process used for the preparation of dry powder formulations for inhalation.

The present invention is a preparation containing a statin-encapsulated nanoparticle obtained by encapsulating statin in a nanoparticle containing a bioabsorbable polymer. The nanoparticle has a number average particle diameter of less than 1000 nm. The preparation is used to enhance the function of a stem cell. The present invention is a stem cell with an enhanced function. The stem cell takes up and contains the statin-encapsulated nanoparticle.

A coated fine particle comprisisng: (i) a complex of a drug and a cationic lipid, wherein (a) the drug is a nucleic acid and the complex is obtained by mixing the drug and the cationic lipid in water, wherein the complex has a diameter of 10 nm to 1,000 nm, and (ii) a lipid layer formed of lipid(s), wherein the lipid(s) is selected from phospholipid, glyceroglycolipid, sphingoglycolipid, cholesterol and synthetic lipid, wherein the complex is coated with the lipid layer.

The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress syndrome.